Origin Materials, Inc.

Origin Materials maintains a debt-free capital structure with a debt-to-equity ratio of 0.0, supported by $19.2 million in cash and equivalents and $13.5 million in marketable securities as of Q1 2026. The current ratio stands at 2.66, indicating adequate short-term liquidity coverage against $19.0 million in current liabilities. However, the company faces substantial going-concern risks, as filings explicitly reference doubt about its ability to continue operations without significant additional financing. The market capitalization of $7.9 million reflects a price-to-book ratio of 0.09, signaling deep distress in equity valuation relative to the $88.3 million in total equity.

Profitability remains severely negative, with a net loss of $17.7 million in Q1 2026, driven by an operating loss of $16.5 million against only $0.5 million in revenue. Return on equity is -2.83 and return on assets is -1.85, reflecting the inability of the current asset base to generate positive returns. The company incurred $1.9 million in losses from the fair value adjustment of convertible notes, further eroding net income. Operating cash flow was negative $4.9 million, while free cash flow declined to -$11.8 million due to $7.0 million in capital expenditures, highlighting the cash-intensive nature of its ongoing operations and facility development.

Revenue concentration is high, with the top two customers accounting for a significant portion of sales, as indicated by disclosed customer concentration risk metrics. The company operates as a single segment, with geographic exposure primarily in the United States and Canada. In Q1 2026, product revenue was $0.5 million, a sharp decline from $5.4 million in the same period of the prior year. This contraction underscores the volatility in demand for its PET closures and intermediate chemicals, alongside challenges in scaling commercial production.

The growth trajectory shows a steep decline in revenue, falling from $5.4 million in Q1 2025 to $0.5 million in Q1 2026. Net loss improved slightly from -$26.4 million to -$17.7 million year-over-year, largely due to a $16.6 million asset impairment charge recorded in Q1 2025 that did not recur in the current period. However, the underlying operational losses remain persistent, with cost of revenues at $0.3 million and operating expenses totaling $16.7 million, including $2.8 million in R&D and $12.7 million in general and administrative costs.

Key risks include high liquidity risk due to the need for substantial additional financing to sustain operations and complete manufacturing facilities. The company faces dilution risk from outstanding warrants and convertible notes, although current dilution risk is assessed as low. Filings highlight substantial doubt about going concern status, dependent on securing project financing and government incentives. Additionally, the company is exposed to regulatory risks related to ESG practices and trade restrictions, which could impact its ability to procure raw materials and scale production cost-effectively.

Recent events include the filing of an 8-K with high-severity items related to material agreements and changes in financial obligations. The company issued convertible notes under a 2025 purchase agreement, with $7.0 million in net convertible notes remaining on the balance sheet. There were no significant news events or transcript observations indicating a shift in strategic direction, but the continued reliance on debt financing and the presence of earnout liabilities suggest ongoing pressure to achieve specific performance milestones to avoid further dilution or default.

Origin Materials, Inc. (ORGN) has recorded a notable addition to its shareholder base, marking the first analysis for the ticker with no prior basis for delta computation. This initial snapshot highlights a specific holder change detected on June 20, 2026, where an investor added a position in the company. The new holding, reported as of March 31, 2026, consists of 387 shares valued at approximately $0.001 million. This position represents a negligible weight of roughly 0.00000068% of the total equity, indicating a minimal impact on the company's overall ownership structure at this stage. Despite this activity, the company currently shows zero analyst coverage and no index memberships, reflecting a limited presence in broader financial tracking systems. The shareholder registry includes nine top holders, but the recent addition does not significantly alter the composition of this group. This development serves as a baseline for future monitoring of ORGN, establishing a reference point for subsequent changes in ownership or market interest. Without prior data for comparison, the significance of this holder change remains isolated to the initial establishment of the tracking record.

Analysts project 3,057.6% upside to a $30 target price, signaling strong confidence in future valuation recovery.

The company maintains a low leverage band with a 0.51 debt-to-equity ratio, reducing financial distress risk.

Capex to revenue ratio of 1.5964 ranks best-in-class among 17 peers, indicating aggressive growth investment.

Dilution risk is assessed as low, suggesting limited immediate pressure on existing shareholder equity value.

Revenue CAGR of 4.2% from FY2023 to FY2025 demonstrates modest top-line growth trajectory over two years.

Liquidity risk is flagged as high, posing significant threats to the company's short-term operational continuity.

FY2025 net income plummeted to -$249.7 million, reflecting severe profitability deterioration and massive losses.

Operating margin of -13.69% places the company in the bottom quartile of its 18-peer chemical cohort.

Free cash flow remained deeply negative at -$63 million in FY2025, highlighting persistent cash burn issues.

Return on equity of -2.83% ranks in the bottom quartile, indicating poor capital efficiency relative to peers.

Revenue $477.0k; Operating income -$16.5M.

• ▍Revenue $477.0k
• ▍Operating income -$16.5M
• ▍Net margin -3700.2%

Revenue $15.9M; Operating income -$64.5M.

• ▍Revenue $15.9M
• ▍Operating income -$64.5M
• ▍Net margin -349.5%

Revenue $11.2M; Operating income -$47.6M.

• ▍Revenue $11.2M
• ▍Operating income -$47.6M
• ▍Net margin -348.6%

Revenue $18.9M; Operating income -$259.1M.

• ▍Revenue $18.9M
• ▍Operating income -$259.1M
• ▍Net margin -1319.6%

Revenue $31.3M; Operating income -$84.9M.

• ▍Revenue $31.3M
• ▍Operating income -$84.9M
• ▍Net margin -267.6%

Revenue $31.3M; Operating income -$84.9M.

• ▍Revenue $31.3M
• ▍Operating income -$84.9M
• ▍Net margin -267.6%

Revenue $28.8M; Operating income -$54.9M.

• ▍Revenue $28.8M
• ▍Operating income -$54.9M
• ▍Net margin 82.6%

Revenue $28.8M; Operating income -$54.9M.

• ▍Revenue $28.8M
• ▍Operating income -$54.9M
• ▍Net margin 82.6%